Leadership & People
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Recent executive moves in the industry include C-suite changes at NervGen Pharma and Phathom Pharmaceuticals and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Janux Therapeutics and PepGen.
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.
Executives On The Move: New Roles Filled at Lisata Therapeutics, Roquefort Therapeutics and Voyager Therapeutics
This week's executive changes in the industry include new CEOs at Roquefort Therapeutics, Lisata Therapeutics and Everest Medicines, while Vyriad and RenovoRx get new chief operating officers.
Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.
The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.
Recent executive changes in the industry include C-suite changes at TherapeuticsMD and Clarity Pharmaceuticals. Meanwhile, new directors were appointed at Metagenomi and Psilotech Health Solutions.
The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.
Recent executive changes in the industry include C-suite changes at Precision Biosciences and Revolution Medicines. Meanwhile, new directors were appointed at Sanofi and Arcutis Biotherapeutics.
Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.
Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.
Recent executive changes in the industry include C-suite changes at Aeglea Biosciences and I-Mab. Meanwhile, new directors were appointed at Altius Healthcare and Vaxart.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.